The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $9.84 billion in 2025 to $11.26 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited awareness of non-viral techniques, emerging biologics development, initial regulatory frameworks for drug delivery, early academic research focus on nanoparticles.
The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $19.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to advancements in polymer-based carriers, growth of rna and dna therapeutics, increasing investment in personalized medicine, expansion of contract development and manufacturing organizations (cdmos), rising collaborations between pharma and academic institutions. Major trends in the forecast period include rising adoption of non-viral delivery platforms for targeted therapies, increasing use of nanoparticles and liposome-based carriers, focus on reducing immune response and enhancing safety, growth in personalized medicine and targeted therapeutics, expansion of cdmos and academic research collaborations.
The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market in the coming years. Personalized medicine is a healthcare approach that customizes treatment based on an individual’s genetic profile, lifestyle, and environmental factors. The demand for personalized medicine is increasing because it enables more effective therapies by addressing the specific underlying causes of disease in each patient. Non-viral drug delivery systems support personalized medicine by enabling the safe and precise delivery of drugs or genetic material to target cells, minimizing risks and improving treatment accuracy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases, up from 6 approvals in 2022. Therefore, the growing demand for personalized medicines is fueling the growth of the non-viral drug delivery systems market.
Major companies operating in the non-viral drug delivery systems market are concentrating on advanced technologies, such as pre-optimized ionizable lipid mix systems, to simplify the development and delivery of RNA-based therapeutics. A pre-optimized ionizable lipid mix system is a formulation technology designed to efficiently encapsulate RNA molecules within lipid nanoparticles, ensuring enhanced stability, protection of the payload, and targeted delivery for gene-based therapeutic applications. For example, in September 2024, Cytiva, a US-based biotechnology company, introduced an RNA delivery lipid nanoparticle (LNP) kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This system features a ready-to-use ionizable lipid mix that enables rapid screening of RNA payloads and effective delivery validation, particularly for infectious disease vaccine development. It integrates seamlessly with automated microfluidic platforms, supports scalable manufacturing using GMP-grade components, and provides protocols along with proof-of-concept data to support users from early discovery through clinical evaluation.
In September 2023, SOHM Inc., a US-based pharmaceutical company, acquired ABBIE from CGA 369 for $10 million. Through this acquisition, SOHM enhanced its capabilities in delivering large genetic payloads using integrase-based, non-viral technologies. ABBIE is being developed as an off-the-shelf gene-editing kit, with commercialization planned for 2024 and human trials expected by late 2025. CGA 369 is a US-based biotechnology company specializing in non-viral, integrase-based gene-editing and genetic payload delivery systems.
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the non-viral drug delivery systems market by increasing the cost of imported materials such as specialized polymers, lipids, and nanoparticles. Segments including RNA-based therapeutics and liposome carriers are most impacted, particularly in regions like Asia-Pacific where manufacturing hubs such as China and India face import duties. This has led to higher production costs and adjustments in supply chains. Positively, tariffs are driving local production, innovation in alternative materials, and greater investment in domestic manufacturing capabilities.
The non-viral drug delivery systems market research report is one of a series of new reports that provides non-viral drug delivery systems market statistics, including non-viral drug delivery systems industry global market size, regional shares, competitors with a non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-viral drug delivery systems refer to approaches for administering therapeutic agents into the body without the use of viral vectors. These systems employ physical, chemical, or mechanical methods such as nanoparticles, liposomes, and polymer-based carriers to safely transport drugs to specific target sites. They are designed to minimize the risks associated with viral delivery, including immune responses and insertional mutagenesis. This strategy improves treatment effectiveness and enhances patient safety across a wide range of medical conditions.
The main types of molecules delivered through non-viral drug delivery systems include biologics and small molecules. Biologics are therapeutics derived from living sources and include proteins, peptides, monoclonal antibodies, and nucleic acid-based therapies such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The biologic types delivered comprise RNA, DNA, proteins or peptides, and antibodies. The key end users include pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), as well as hospitals and clinics.
The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $19.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to advancements in polymer-based carriers, growth of rna and dna therapeutics, increasing investment in personalized medicine, expansion of contract development and manufacturing organizations (cdmos), rising collaborations between pharma and academic institutions. Major trends in the forecast period include rising adoption of non-viral delivery platforms for targeted therapies, increasing use of nanoparticles and liposome-based carriers, focus on reducing immune response and enhancing safety, growth in personalized medicine and targeted therapeutics, expansion of cdmos and academic research collaborations.
The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market in the coming years. Personalized medicine is a healthcare approach that customizes treatment based on an individual’s genetic profile, lifestyle, and environmental factors. The demand for personalized medicine is increasing because it enables more effective therapies by addressing the specific underlying causes of disease in each patient. Non-viral drug delivery systems support personalized medicine by enabling the safe and precise delivery of drugs or genetic material to target cells, minimizing risks and improving treatment accuracy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases, up from 6 approvals in 2022. Therefore, the growing demand for personalized medicines is fueling the growth of the non-viral drug delivery systems market.
Major companies operating in the non-viral drug delivery systems market are concentrating on advanced technologies, such as pre-optimized ionizable lipid mix systems, to simplify the development and delivery of RNA-based therapeutics. A pre-optimized ionizable lipid mix system is a formulation technology designed to efficiently encapsulate RNA molecules within lipid nanoparticles, ensuring enhanced stability, protection of the payload, and targeted delivery for gene-based therapeutic applications. For example, in September 2024, Cytiva, a US-based biotechnology company, introduced an RNA delivery lipid nanoparticle (LNP) kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This system features a ready-to-use ionizable lipid mix that enables rapid screening of RNA payloads and effective delivery validation, particularly for infectious disease vaccine development. It integrates seamlessly with automated microfluidic platforms, supports scalable manufacturing using GMP-grade components, and provides protocols along with proof-of-concept data to support users from early discovery through clinical evaluation.
In September 2023, SOHM Inc., a US-based pharmaceutical company, acquired ABBIE from CGA 369 for $10 million. Through this acquisition, SOHM enhanced its capabilities in delivering large genetic payloads using integrase-based, non-viral technologies. ABBIE is being developed as an off-the-shelf gene-editing kit, with commercialization planned for 2024 and human trials expected by late 2025. CGA 369 is a US-based biotechnology company specializing in non-viral, integrase-based gene-editing and genetic payload delivery systems.
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the non-viral drug delivery systems market by increasing the cost of imported materials such as specialized polymers, lipids, and nanoparticles. Segments including RNA-based therapeutics and liposome carriers are most impacted, particularly in regions like Asia-Pacific where manufacturing hubs such as China and India face import duties. This has led to higher production costs and adjustments in supply chains. Positively, tariffs are driving local production, innovation in alternative materials, and greater investment in domestic manufacturing capabilities.
The non-viral drug delivery systems market research report is one of a series of new reports that provides non-viral drug delivery systems market statistics, including non-viral drug delivery systems industry global market size, regional shares, competitors with a non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-viral drug delivery systems refer to approaches for administering therapeutic agents into the body without the use of viral vectors. These systems employ physical, chemical, or mechanical methods such as nanoparticles, liposomes, and polymer-based carriers to safely transport drugs to specific target sites. They are designed to minimize the risks associated with viral delivery, including immune responses and insertional mutagenesis. This strategy improves treatment effectiveness and enhances patient safety across a wide range of medical conditions.
The main types of molecules delivered through non-viral drug delivery systems include biologics and small molecules. Biologics are therapeutics derived from living sources and include proteins, peptides, monoclonal antibodies, and nucleic acid-based therapies such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The biologic types delivered comprise RNA, DNA, proteins or peptides, and antibodies. The key end users include pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), as well as hospitals and clinics.
The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Non-Viral Drug Delivery Systems Market Characteristics
3. Non-Viral Drug Delivery Systems Market Supply Chain Analysis
4. Global Non-Viral Drug Delivery Systems Market Trends and Strategies
5. Non-Viral Drug Delivery Systems Market Analysis of End Use Industries
7. Global Non-Viral Drug Delivery Systems Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Non-Viral Drug Delivery Systems Total Addressable Market (TAM) Analysis for the Market
9. Non-Viral Drug Delivery Systems Market Segmentation
10. Non-Viral Drug Delivery Systems Market Regional and Country Analysis
11. Asia-Pacific Non-Viral Drug Delivery Systems Market
12. China Non-Viral Drug Delivery Systems Market
13. India Non-Viral Drug Delivery Systems Market
14. Japan Non-Viral Drug Delivery Systems Market
15. Australia Non-Viral Drug Delivery Systems Market
16. Indonesia Non-Viral Drug Delivery Systems Market
17. South Korea Non-Viral Drug Delivery Systems Market
18. Taiwan Non-Viral Drug Delivery Systems Market
19. South East Asia Non-Viral Drug Delivery Systems Market
20. Western Europe Non-Viral Drug Delivery Systems Market
21. UK Non-Viral Drug Delivery Systems Market
22. Germany Non-Viral Drug Delivery Systems Market
23. France Non-Viral Drug Delivery Systems Market
24. Italy Non-Viral Drug Delivery Systems Market
25. Spain Non-Viral Drug Delivery Systems Market
26. Eastern Europe Non-Viral Drug Delivery Systems Market
27. Russia Non-Viral Drug Delivery Systems Market
28. North America Non-Viral Drug Delivery Systems Market
29. USA Non-Viral Drug Delivery Systems Market
30. Canada Non-Viral Drug Delivery Systems Market
31. South America Non-Viral Drug Delivery Systems Market
32. Brazil Non-Viral Drug Delivery Systems Market
33. Middle East Non-Viral Drug Delivery Systems Market
34. Africa Non-Viral Drug Delivery Systems Market
36. Non-Viral Drug Delivery Systems Market Competitive Landscape and Company Profiles
37. Non-Viral Drug Delivery Systems Market Other Major and Innovative Companies
40. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Non-Viral Drug Delivery Systems Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-viral drug delivery systems? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral drug delivery systems market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type Of Molecule Delivered: Biologics; Small Molecules2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA); Proteins or Peptides; Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Development And Manufacturing Organizations (CDMOs); Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides; Proteins; Monoclonal Antibodies; RNA-based Therapeutics; DNA-based Therapies2) By Small Molecules: Chemotherapeutics; Anti-inflammatories; Antivirals; Antibiotics; Hormonal Drugs
Companies Mentioned: Evonik Industries AG; Cytiva; Arcturus Therapeutics Holdings Inc.; CureVac N.V.; PolyPid Ltd; Ethris GmbH; Entos Pharmaceuticals Inc.; Liquidia Technologies Inc.; ReCode Therapeutics Inc.; Enable Injections Inc.; GenEdit Inc.; N4 Pharma Plc; Hopewell Therapeutics Inc.; Tiba Biotech LLC; Vesigen Therapeutics Inc.; Carmine Therapeutics Inc.; Evox Therapeutics Ltd; InnoCore Pharmaceuticals BV; Nanomerics Ltd; DelSiTech Ltd; Curapath Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Non-Viral Drug Delivery Systems market report include:- Evonik Industries AG
- Cytiva
- Arcturus Therapeutics Holdings Inc.
- CureVac N.V.
- PolyPid Ltd
- Ethris GmbH
- Entos Pharmaceuticals Inc.
- Liquidia Technologies Inc.
- ReCode Therapeutics Inc.
- Enable Injections Inc.
- GenEdit Inc.
- N4 Pharma Plc
- Hopewell Therapeutics Inc.
- Tiba Biotech LLC
- Vesigen Therapeutics Inc.
- Carmine Therapeutics Inc.
- Evox Therapeutics Ltd
- InnoCore Pharmaceuticals BV
- Nanomerics Ltd
- DelSiTech Ltd
- Curapath Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.26 Billion |
| Forecasted Market Value ( USD | $ 19.07 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
